The register of patients suffering from heart failure in St. Petersburg ”persona-chf”: interim results
- 作者: Koltsov A.V.1, Tyrenko V.V.1
-
隶属关系:
- Kirov Military Medical Academy
- 期: 卷 25, 编号 4 (2023)
- 页面: 595-602
- 栏目: Research paper
- ##submission.dateSubmitted##: 25.07.2023
- ##submission.dateAccepted##: 01.10.2023
- ##submission.datePublished##: 11.01.2024
- URL: https://journals.eco-vector.com/1682-7392/article/view/562963
- DOI: https://doi.org/10.17816/brmma562963
- ID: 562963
如何引用文章
详细
The prevalence of heart failure is becoming global, and the number of patients is steadily increasing annually. The assessment of the number of patients suffering from heart failure in St. Petersburg, as well as their characteristics, is one of the most important tasks for which the Saint Petersburg Register of Patients Suffering from Chronic Heart Failure, PERSONA-CHF, was developed and initiated. Data analysis was performed for the period from February to May 2023. A total of 158 people comprised the sample. The Hospital for War Veterans (Saint Petersburg) participated in the pilot project. The average age of the patients was 81. 14 ± 11. 39 years. The number of points based on the assessment scale of the patient’s clinical condition was 6. 4 ± 2. 6. The average left ventricular ejection fraction was 59. 1% ± 11. 1%. Moreover, >70% of patients had a left ventricular ejection fraction of >50%, and in 23. 4% of patients, it was even higher than 65%. Comorbid pathologies prevailed: hypertension, 93%; coronary heart disease, 79. 1%; chronic kidney disease, 46. 8%; atrial fibrillation, 32. 9%; anemia, 31. 6%; and diabetes mellitus, 24. 7%. A high percentage of the presence of comorbid pathology leads to the need to modify therapy and use modern groups of drugs. Beta-blockers were most often prescribed (86. 7%), diuretics (75. 3%), mineralocorticoid receptor antagonists (62%), angiotensin-converting enzyme inhibitors (61. 4%), and angiotensin II receptor blockers (39. 2%). The appointment of modern groups of drugs, such as angiotensin receptor-non-lysine inhibitor and sodium-glucose cotransporter inhibitor 2-type, was 5. 1%. Attention was drawn to the lack of continuity in the provision of medical care and low compliance of patients with modern quadrotherapy, given its high cost for the patient. In general, the efficiency of the PERSONA-CHF registry platform is quite good and allows us to more accurately understand the epidemiological aspects of heart failure, the solution of which will make it possible to improve the quality of medical care, identify the need for necessary medicines, and reduce mortality and mortality rates. However, a much larger set of patients and a different profile of medical institutions are required for the most complete understanding of the problem of heart failure in Saint Petersburg, since the Hospital for War Veterans reflects only a small sample of patients, mainly of senile age, and several comorbid pathologies. In addition, this register requires further improvement to increase the number of connected medical organizations, expand the number of analyzed parameters, automate the process, and possibly connect artificial intelligence for data analysis.
全文:
![受限制的访问](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
作者简介
Andrew Koltsov
Kirov Military Medical Academy
编辑信件的主要联系方式.
Email: Andrewkoltsov83@gmail.com
ORCID iD: 0000-0001-9881-4587
SPIN 代码: 8988-4988
MD, Cand. Sci. (Med.)
俄罗斯联邦, Saint PetersburgVadim Tyrenko
Kirov Military Medical Academy
Email: vadim_tyrenko@mail.ru
ORCID iD: 0000-0002-0470-1109
SPIN 代码: 3022-5038
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, Saint Petersburg参考
- Ageev FT, Belenkov YuN, Fomin IV, et al. Prevalence of chronic heart failure in the European part of the Russian Federation: data from EPOCH-CHF. Russian Heart Failure Journal. 2006;7(1):112–115. (In Russ.).
- Tereshchenko SN, Galyavich AS, Uskach TM, et al. 2020 clinical practice guidelines for chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311–374. (In Russ.). doi: 10.15829/1560-4071-2020-4083
- Mareev VYu, Fomin IV, Ageev FT, et al. Chronic heart failure (CHF). Journal of Heart Failure. 2017;18(1):3–40. (In Russ.). doi: 10.18087/rhfj.2017.1.2346
- World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191–2194. doi: 10.1001/jama.2013.281053
- Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2022;10(2):73–84. doi: 10.1016/j.jchf.2021.09.004
- McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi: 10.1056/NEJMoa1409077
- Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOMER trial. Eur Heart J. 2016;37(19):1526–1534. doi: 10.1093/eurheartj/ehv728
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720
- Batyushin MM. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the dapa-ckd study. Terapevticheskii Arkhiv. 2021;93(6):713–723. (In Russ.). doi: 10.26442/00403660.2021.6.200891
- Salukhov VV, Khalimov YS, Shustov SB, Popov SI. SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients. Diabetes Mellitus. 2021;23(5):475–491. (In Russ.). doi: 10.14341/DM12123
- Upravlenie Federal’noi sluzhby gosudarstvennoi statistiki po g. Sankt-Peterburgu i Leningradskoi oblasti (Petrostat). Vozrastno-polovoi sostav naseleniya Sankt-Peterburga na 1 yanvarya 2021 goda: statisticheskii byulleten’. Saint Peterburg: Petrostat; 2021. 57 p. (In Russ.).
补充文件
![](/img/style/loading.gif)